The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Another Biotech transaction:
Larimar Therapeutics, Inc. (NASDAQ:LRMR), a biotech firm specializing in treatments for rare diseases, has initiated an underwritten public offering of its common stock and pre-funded warrants.
On the day of Oppenheim conference.
Pre AACR, the "new Avacta " will very soon be very clear and a complete re- rating of Avacta therapeutics inc. in place.
From market :
Has anyone questioned why London-based #AVCT has recently appointed a full time ‘Head of Research and Development’ based in 🇺🇸?
A role that oversees ‘all clinical development and pre-clinical research activities of the Therapeutics Division’.
Gene editing start-up Metagenomi and cancer specialist NeOnc Technologies have announced the terms of their initial public offerings, in another sign that investor interest in biotech is growing.The company has Moderna, Novo and Bayer among their backers.
This will be of relevance to Avacta's and Daewoong's JV : Affyxell and how the market could remind themselves of the upside in IPO valuation, now with Biocytogen gene editing on board as well.
Will be a great two months before AACR gathering.
Feb 6 (Reuters) - Drugmaker Novartis AG (NOVN.S), opens new tab said it will acquire MorphoSys AG (MORG.DE), opens new tab, a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), adding a promising rare bone-marrow cancer treatment candidate to its portfolio.
Reuters first reported on Monday that Switzerland-based Novartis was in advanced talks to acquire MorphoSys, leading to the German biotech firm's shares surging more than 40%.
FYI:
Ref BCYC: book runners were Goldman Sachs & Co. LLC, Morgan Stanley and SVB Leerink acted as joint book-running managers for the offering. JMP Securities acted as co-manager for the offering.
With new head of Therapeutics in place at Avacta: she will be speaking to them.
Https://www.biopharmadive.com/news/lupus-cell-therapy-car-t-biotech-startups/705767/